Clinical Trial Update: Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing bone response in metastatic castration-resistant prostate cancer patients treated with cabozantinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Alfredo Berruti | Conditions: Carcinoma Prostate | Phase 2 | Status: COMPLETED